全文获取类型
收费全文 | 3223篇 |
免费 | 185篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 73篇 |
妇产科学 | 80篇 |
基础医学 | 595篇 |
口腔科学 | 111篇 |
临床医学 | 283篇 |
内科学 | 714篇 |
皮肤病学 | 47篇 |
神经病学 | 337篇 |
特种医学 | 81篇 |
外科学 | 182篇 |
综合类 | 29篇 |
一般理论 | 1篇 |
预防医学 | 241篇 |
眼科学 | 58篇 |
药学 | 297篇 |
中国医学 | 20篇 |
肿瘤学 | 258篇 |
出版年
2024年 | 4篇 |
2023年 | 30篇 |
2022年 | 117篇 |
2021年 | 183篇 |
2020年 | 95篇 |
2019年 | 116篇 |
2018年 | 112篇 |
2017年 | 79篇 |
2016年 | 121篇 |
2015年 | 110篇 |
2014年 | 170篇 |
2013年 | 193篇 |
2012年 | 285篇 |
2011年 | 314篇 |
2010年 | 167篇 |
2009年 | 101篇 |
2008年 | 225篇 |
2007年 | 193篇 |
2006年 | 198篇 |
2005年 | 162篇 |
2004年 | 139篇 |
2003年 | 116篇 |
2002年 | 96篇 |
2001年 | 13篇 |
2000年 | 3篇 |
1999年 | 4篇 |
1998年 | 10篇 |
1997年 | 7篇 |
1996年 | 4篇 |
1995年 | 7篇 |
1994年 | 9篇 |
1993年 | 4篇 |
1992年 | 3篇 |
1990年 | 2篇 |
1989年 | 5篇 |
1988年 | 3篇 |
1987年 | 4篇 |
1986年 | 2篇 |
1985年 | 1篇 |
1984年 | 2篇 |
1983年 | 3篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1979年 | 3篇 |
1977年 | 1篇 |
1975年 | 1篇 |
1973年 | 1篇 |
1971年 | 1篇 |
1970年 | 2篇 |
排序方式: 共有3428条查询结果,搜索用时 0 毫秒
31.
Wendy van Dorp Ivana M.M. van der Geest Joop S.E. Laven Wim C.J. Hop Sebastian J.C.M.M. Neggers Andrica C.H. de Vries Rob Pieters Marry M. van den Heuvel-Eibrink 《European journal of cancer (Oxford, England : 1990)》2013,49(6):1280-1286
BackgroundAlthough gonadal toxicity has been reported, no data are available on recovery of gonadal function in very long-term survivors of childhood cancer. Inhibin B is a novel reliable serum marker which has been shown to be of value in childhood cancer survivor studies to identify risk groups for impaired gonadal function, but consecutive long-term follow-up studies using serum inhibin B as a marker are not available.ObjectiveTo evaluate possible recovery of gonadal dysfunction over time in adult male survivors of childhood cancer.MethodsIn this retrospective study, adult male long-term childhood cancer survivors (n = 201) who visited our outpatient late effects clinic were included and we used inhibin B as a surrogate marker for gonadal function.ResultsMedian age at diagnosis was 5.9 years (range 0.0–17.5) and discontinuation of treatment was reached at a median age of 8.2 years (range 0.0–20.8). Inhibin B levels were first measured after a median follow-up time of 15.7 years (range 3.0–37.0). Median interval between the first (T1) and second measurement (T2) was 3.3 years (range 0.7–11.3). Median inhibin B level was 127 ng/L (range 5–366) at T1 and 155 ng/L (range 10–507) at T2. The prediction model suggests that inhibin B levels do not normalise in survivors with a very low Inhibin B level at T1.ConclusionsOur results suggest that recovery of gonadal function is possible even long after discontinuation of treatment. However, this recovery does not seem to occur in survivors who already reached critically low inhibin B levels after discontinuation of treatment. 相似文献
32.
33.
34.
Diaz LA Spinsanti LI Almiron WR Contigiani MS 《Revista do Instituto de Medicina Tropical de S?o Paulo》2003,45(2):109-110
Una virus (UNAV), Togaviridae family, is widely distributed in South America, where infections have been detected in mosquitoes and vertebrate hosts (humans, birds and horses). We analyzed human sera from Córdoba inhabitants aged 44 to 89 years and using a neutralization test, we found a prevalence of UNAV antibodies of 3.8% (3/79). The low titers detected suggest past infections probably acquired in rural areas of the Province of Córdoba (central Argentina). None sera were found positive for MAYV neutralizing antibodies. This is the first report of human infections by UNAV in Argentina. 相似文献
35.
36.
Rissanen TT Korpisalo P Markkanen JE Liimatainen T Ordén MR Kholová I de Goede A Heikura T Gröhn OH Ylä-Herttuala S 《Circulation》2005,112(25):3937-3946
37.
Dunić I Djurković-Djaković O Vesić S Zerjav S Jevtović D 《International journal of STD & AIDS》2005,16(7):475-478
A prospective study to evaluate the incidence of herpes zoster (HZ) as an immune restoration disease in patients with AIDS during highly active antiretroviral therapy (HAART) was conducted in a series of 115 patients diagnosed with AIDS initiated on HAART between 1 January 2000 and 31 July 2001. Of these, a single dermatomal HZ episode occurred in 14 (12%) patients within one and 15 months of HAART (median eight months). The HZ patients were similar to the non-HZ patients in age, sex, and HIV transmission risk factor, but had a more advanced disease. Compared with the baseline values, the viral loads significantly (P<0.01) decreased, while the mean CD4+ T-cell counts increased by almost four-fold (P<0.01) in both groups at the time of the HZ episode (or equivalent in non-HZ), but remained below 400/mL in the HZ patients. HZ during HAART is an immunopathological consequence of the improvement of the host immuneresponse, correlating with the beginning of immune restoration. 相似文献
38.
Rodríguez-Nóvoa S Morello J Barreiro P Maida I García-Gascó P Vispo E González-Pardo G Parra A Jiménez-Nácher I Soriano V 《AIDS research and human retroviruses》2008,24(6):821-825
Plasma concentration of atazanavir (ATV) may be reduced when coadministered with tenofovir (TDF) or proton pump inhibitors. Boosting ATV exposure with ritonavir (r) may make it possible to overcome these drug interactions. However, jaundice and loss of the metabolic advantages of ATV are more frequent using ATV/r than ATV alone. Herein, we assessed whether therapeutic drug monitoring (TDM) could make it possible to identify the subset of patients in whom removal of ritonavir could be attempted without risk of suboptimal plasma ATV exposure and subsequent virological failure. A total of 56 patients with undetectable plasma HIV-RNA under a stable triple regimen containing ATV 300/100 mg qd were switched to ATV 400 mg qd. Plasma ATV concentrations were measured using a reliable high-performance liquid chromatography method. Median plasma ATV C(min) fell from 880 to 283 ng/ml (p = 0.03) after removal of ritonavir. While all patients on ATV/r showed ATV plasma concentrations within therapeutic values (IC(min) above 150 ng/ml) before switching, four patients (7%) fell below this threshold after switching to ATV 400 mg qd. However, only one of this group experienced virological failure at week 24 of follow-up. TDF was part of the antiretroviral regimen in all four cases. From a total of 29 (52%) patients on ATV/r showing grade 3-4 hyperbilirubinemia, only 7 (12%) remained on it upon switching to ATV 400 mg qd (p < 0.001). Patients with complete viral suppression under ATV/r 300/100 mg qd may benefit from switching to ATV 400 mg qd guided by TDM, which may make it possible to minimize adverse events without compromising antiviral efficacy in most cases. 相似文献
39.
Maria T. Rinaudo Magda Curto Ivana Rabbone Marco Piccinini Renato Bruno Silvia Mioletti Silvia Gamba 《Journal of diabetes and its complications》1994,8(4):221-225
In circulating lymphocytes from patients with non-insulin-dependent diabetes mellitus (NIDDM) subnormal pyruvate dehydrogenase (PDH) activity returns to normal following patient treatment with sulfonylurea (gliclazide*, 80 mg twice daily/5 weeks). Moreover, in vitro in cells from diabetic patients exposed to insulin at 50 μU/mL PDH activation also occurs; in cells of controls the same happens for insulin at 5 μU/mL, whereas at 50 μU/mL inhibition takes place. Therefore, the low PDH activity in cells of NIDDM patients might be caused by defective insulin control on the enzyme and its recovery in gliclazide-treated patients by drug-mediated removal of the defect. The validity of the hypothesis was verified in this study where cells of NIDDM patients before and after gliclazide treatment were exposed, in vitro, to insulin at 5 and 50 μU/mL and then tested for PDH activity. In such conditions, the profile of PDH behavior in treated patients was no longer comparable to that in untreated patients but closer to that in euglycemic controls, thus supporting the view that the recovery of PDH activity in NIDDM patients following gliclazide treatment might be the expression of an additional effect that the drug would have in these patients, aimed to renew cell responsiveness to insulin. 相似文献